MUC16 and gastric cancer: Although being a FLAGS gene, MUC16 mutations were previously associated with improved prognosis, as it enhances the antitumor immune responses through cytotoxic T lymphocytes in endometrial (51) and gastric cancers (52) and was associated with better response and treatment outcomes after therapy with immune checkpoint inhibitors (53).